Abstract: Embodiments of the invention are directed to methods, systems and computer programs that provide improved risk stratification for people having elevated large HDL-P using at least one defined HDL risk interaction parameter.
Abstract: Methods, computer program products and apparatus determine a subject's risk of having or developing CHD using a calculated HDL particle risk number and/or a mathematical model of risk associated with HDL particles that adjusts concentrations of at least one of the subclasses of small, medium and large HDL particle measurements to reflect predicted CHD risk. A calculated LDL particle risk number may also be generated as well as a lipoprotein particle index derived from the ratio of RLDL/RHDL.
Abstract: The clinical analyzers automatically electronically monitor selected parameters and automatically electronically adjust parameters to maintain the analyzer within desired operational ranges. The clinical NMR analyzers can be configured as a networked system with a plurality of clinical NMR analyzers located at different use sites.
Type:
Application
Filed:
June 25, 2019
Publication date:
October 17, 2019
Applicant:
LipoScience, Inc.
Inventors:
James D. Otvos, Elias J. Jeyarajah, Stephen Markham, Steven P. Matyus, David R. Morgan, Bruce D. Silberman, Donald R. Deuel
Abstract: Embodiments of the invention are directed to methods, systems and computer programs that provide improved risk stratification for people having elevated large HDL-P using at least one defined HDL risk interaction parameter.
Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.
Type:
Grant
Filed:
May 3, 2016
Date of Patent:
August 20, 2019
Assignee:
LipoScience, Inc.
Inventors:
James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier
Abstract: The clinical analyzers automatically electronically monitor selected parameters and automatically electronically adjust parameters to maintain the analyzer within desired operational ranges. The clinical NMR analyzers can be configured as a networked system with a plurality of clinical NMR analyzers located at different use sites.
Type:
Grant
Filed:
March 6, 2014
Date of Patent:
July 30, 2019
Assignee:
LipoScience, Inc.
Inventors:
James D. Otvos, Elias J. Jeyarajah, Stephen Markham, Steven P. Matyus, David R. Morgan, Bruce D. Silberman, Donald R. Deuel
Abstract: Methods, systems and circuits evaluate a subject's CVD risk using a risk parameter that includes at least one HDL and inflammatory biomarker interaction parameter. The inflammatory biomarker may optionally comprise NMR derived measurements of GlycA from at least one biosample of the subject. The risk parameter may be gender-specific.
Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes using defined mathematical models of short term risk (STR) and longer term risk of progression. The evaluations can stratify risk for patients having the same glucose measurement, particularly those with intermediate or low (normal) fasting plasma glucose (FPG) values. The STR or IR (insulin resistance) model(s) may include an inflammatory biomarker such as an NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject. Embodiments of the invention also provide methods, systems and circuits that generate STR scores as a marker of beta-cell dysfunction or impairment.
Abstract: Methods, systems and circuits evaluate a subject's CVD risk using a risk parameter that includes at least one HDL and inflammatory biomarker interaction parameter. The inflammatory biomarker may optionally comprise NMR derived measurements of GlycA from at least one biosample of the subject. The risk parameter may be gender-specific.
Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes using defined mathematical models of short term risk (STR) and longer term risk of progression. The evaluations can stratify risk for patients having the same glucose measurement, particularly those with intermediate or low (normal) fasting plasma glucose (FPG) values. The STR or IR (insulin resistance) model(s) may include an inflammatory biomarker such as an NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject. Embodiments of the invention also provide methods, systems and circuits that generate STR scores as a marker of beta-cell dysfunction or impairment.
Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.
Type:
Grant
Filed:
June 7, 2013
Date of Patent:
October 17, 2017
Assignee:
LipoScience, Inc.
Inventors:
James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier
Abstract: NMR analyzers and associated methods, circuits and computer program products that allow NMR operation in fluctuating ambient temperature environments of at least +/?5 degrees F. in a relatively large operating temperature range, typically between about 60-85 degrees F.) with the ability to still generate accurate quantitative measurements using an electronically applied temperature sensitivity adjustment based on an a priori model of temperature sensitivity and a detected temperature proximate the NMR signal acquisition (e.g., scan). The clinical NMR analyzers can be remotely accessed to evaluate linearity and temperature compensation adjustments.
Abstract: NMR analyzers and associated methods, circuits and computer program products that allow NMR operation in fluctuating ambient temperature environments of at least +/?5 degrees F. in a relatively large operating temperature range, typically between about 60-85 degrees F.) with the ability to still generate accurate quantitative measurements using an electronically applied temperature sensitivity adjustment based on an a priori model of temperature sensitivity and a detected temperature proximate the NMR signal acquisition (e.g., scan). The clinical NMR analyzers can be remotely accessed to evaluate linearity and temperature compensation adjustments.
Abstract: A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 ?M or urine with a normal biologic range of between about 0-1000 ?M.
Type:
Grant
Filed:
May 16, 2013
Date of Patent:
January 10, 2017
Assignee:
LIPOSCIENCE, INC.
Inventors:
James D. Otvos, Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Steven P. Matyus, Stanley L. Hazen
Abstract: A defined peak region residing between about 3.2 and 3.4 ppm of a proton NMR spectrum of an in vitro biosample is electronically evaluated to determine a level of trimethylamine-N-oxide (“TMAO”). The biosamples may be any suitable biosamples including human serum with a normal biologic range of between about 1-50 ?M or urine with a normal biologic range of between about 0-1000 ?M.
Type:
Grant
Filed:
March 13, 2013
Date of Patent:
January 3, 2017
Assignee:
LIPOSCIENCE, INC.
Inventors:
James D. Otvos, Elias J. Jeyarajah, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Dennis W. Bennett, Stanley L. Hazan
Abstract: Embodiments of the invention are directed to methods, systems and computer programs that provide improved risk stratification for people having elevated large HDL-P using at least one defined HDL risk interaction parameter.
Abstract: Embodiments of the invention are directed to improved discrimination of protective (anti-atherogenic) HDL from atherogenic or non-protective (NP) HDL. The methods, systems and computer program products determine protective high density lipoprotein particle (HDL-P) numbers. The methods include obtaining concentration measurements of at least twenty subpopulations of HDL-P subclasses in a blood plasma or serum sample and calculating a protective HDL-P number using (i) a defined subset of the obtained HDL-P concentration measurements or (ii) a zero or defined weighting factor below 1 for HDL-P concentration measurements for HDL subclasses associated with particle sizes above about 11 nm.
Abstract: Biomarkers and/or risk assessments identify patients having an increased risk of certain clinical disease states including, for example, CHD, type 2 diabetes, dementia, or all-cause death (ACD) using NMR signal to measure a level of “GlycA” in arbitrary units or in defined units (e.g., ?mol/L) that can be determined using a defined single peak region of proton NMR spectra. The GlycA measurement can be used as an inflammation biomarker for clinical disease states. The NMR signal for GlycA can include a fitting region of signal between about 2.080 ppm and 1.845 ppm of the proton NMR spectra.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
October 18, 2016
Assignee:
LIPOSCIENCE, INC.
Inventors:
James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore
Abstract: Methods, computer program products and apparatus determine a subject's risk of having or developing CHD using a calculated HDL particle risk number and/or a mathematical model of risk associated with HDL particles that adjusts concentrations of at least one of the subclasses of small, medium and large HDL particle measurements to reflect predicted CHD risk. A calculated LDL particle risk number may also be generated as well as a lipoprotein particle index derived from the ratio of RLDL/RHDL.
Abstract: Methods, systems and circuits evaluate a subject's risk of developing type 2 diabetes or developing or having prediabetes using at least one defined mathematical model of risk of progression that can stratify risk for patients having the same glucose measurement. The model may include NMR derived measurements of GlycA and a plurality of selected lipoprotein components of at least one biosample of the subject.
Type:
Grant
Filed:
March 14, 2013
Date of Patent:
June 7, 2016
Assignee:
LIPOSCIENCE, INC.
Inventors:
James D. Otvos, Irina Y. Shalaurova, Dennis W. Bennett, Justyna E. Wolak-Dinsmore, Thomas M. O'Connell, Kelly Mercier